Cargando…

A polymorphism in ABCC4 is related to efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer patients

To investigate the association of microRNA (miRNA) binding-site polymorphisms in the drug transporter genes with the efficacy of 5-Fluorouracil (5-FU)/capecitabine-based chemotherapy in colorectal cancer (CRC), 6 polymorphisms were determined in 432 CRC patients by using DNA sequencing method. The i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Qi, Meng, Fanyi, Wang, Lei, Mao, Yong, Zhou, Huan, Hua, Dong, Zhang, Hongjian, Wang, Weipeng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539293/ https://www.ncbi.nlm.nih.gov/pubmed/28765596 http://dx.doi.org/10.1038/s41598-017-07491-3

Ejemplares similares

Rs7911488 modified the efficacy of capecitabine-based therapy in colon cancer through altering miR-1307-3p and TYMS expression
por: Chen, Qi, et al.
Publicado: (2017)

The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients
por: Mao, Yong, et al.
Publicado: (2017)

ABCC2-24C > T polymorphism is associated with the response to platinum/5-Fu-based neoadjuvant chemotherapy and better clinical outcomes in advanced gastric cancer patients
por: Li, Ziyu, et al.
Publicado: (2016)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial
por: Madi, A, et al.
Publicado: (2012)

5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine
por: Yoshida, Yoichiro, et al.
Publicado: (2020)

Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports
por: Brickell, K, et al.
Publicado: (2003)

Comparison of the Efficacy of Oral Capecitabine versus Bolus 5-FU in Preoperative Radiotherapy of Locally Advanced Rectal Cancer
por: Kim, Jae-Sung, et al.
Publicado: (2006)

SRSF3 Promotes Angiogenesis in Colorectal Cancer by Splicing SRF
por: Chen, Yinshuang, et al.
Publicado: (2022)

Polymorphisms in TYMS for Prediction of Capecitabine-Induced Hand-Foot Syndrome in Chinese Patients with Colorectal Cancer
por: Dong, Si-Qi, et al.
Publicado: (2021)

TGF-β1 promotes colorectal cancer immune escape by elevating B7-H3 and B7-H4 via the miR-155/miR-143 axis
por: Zhou, Xinru, et al.
Publicado: (2016)

Effects of polymorphisms in the MTHFR gene on 5-FU hematological toxicity and efficacy in Thai colorectal cancer patients
por: Atasilp, Chalirmporn, et al.
Publicado: (2022)

METTL3 antagonizes 5-FU chemotherapy and confers drug resistance in colorectal carcinoma
por: Li, Min, et al.
Publicado: (2022)

METTL3 antagonizes 5-FU chemotherapy and confers drug resistance in colorectal carcinoma
por: Li, Min, et al.
Publicado: (2023)

Metronomic chemotherapy with capecitabine for metastatic colorectal cancer in very elderly patients
por: Jung, Yun Hwa, et al.
Publicado: (2017)

Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review
por: Cura, Yasmin, et al.
Publicado: (2023)

Prolonged Capecitabine Chemotherapy Following Capecitabine and Oxaliplatin (CAPOX) Regimen Chemotherapy Failed to Improve Survival of Stage III Colorectal Cancer After Radical Resection
por: Xu, Ju Ling, et al.
Publicado: (2019)

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer
por: Stoehlmacher, J, et al.
Publicado: (2004)

Role of capecitabine in treating metastatic colorectal cancer in Chinese patients
por: Wang, Feng, et al.
Publicado: (2014)

CD16 expression on neutrophils predicts treatment efficacy of capecitabine in colorectal cancer patients
por: Lu, Yu, et al.
Publicado: (2020)

Chemosensitization of HT29 and HT29-5FU Cell Lines by a Combination of a Multi-Tyrosine Kinase Inhibitor and 5FU Downregulates ABCC1 and Inhibits PIK3CA in Light of Their Importance in Saudi Colorectal Cancer
por: Abdalla, Ashraf N., et al.
Publicado: (2021)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis
por: Xu, Rongzhong, et al.
Publicado: (2017)

Effect of ABCB1 and ABCC3 Polymorphisms on Osteosarcoma Survival after Chemotherapy: A Pharmacogenetic Study
por: Caronia, Daniela, et al.
Publicado: (2011)

Capecitabine in the management of colorectal cancer
por: Hirsch, Bradford R, et al.
Publicado: (2011)

Wnt pathway is involved in 5-FU drug resistance of colorectal cancer cells
por: He, Lingfeng, et al.
Publicado: (2018)

Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy
por: Treenert, Apatsara, et al.
Publicado: (2018)

Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy
por: Lang, Tianqun, et al.
Publicado: (2023)

Preliminary results on anal cancer by applying intensity modulated radiotherapy and synchronous capecitabine chemotherapy simultaneously
por: Xu, Wei-Dong, et al.
Publicado: (2020)

Milk and Egg Are Risk Factors for Adverse Effects of Capecitabine-Based Chemotherapy in Chinese Colorectal Cancer Patients
por: Xu, Jinrong, et al.
Publicado: (2022)

Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma
por: Xu, Leilei, et al.
Publicado: (2018)

FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10
por: Xie, Tao, et al.
Publicado: (2016)

ABCC9 Is Downregulated and Prone to Microsatellite Instability on ABCC9tetra in Canine Breast Cancer
por: Hao, Pan, et al.
Publicado: (2022)

miR-329 regulates the sensitivity of 5-FU in chemotherapy of colorectal cancer by targeting E2F1
por: Yin, Jie, et al.
Publicado: (2018)

Genetic Polymorphism of GSTP1: Prediction of Clinical Outcome to Oxaliplatin/5-FU-based Chemotherapy in Advanced Gastric Cancer
por: Li, Qing-Fang, et al.
Publicado: (2010)

Traditional Chinese medicines and capecitabine‐based chemotherapy for colorectal cancer treatment: A meta‐analysis
por: Jiang, Hui‐Zhong, et al.
Publicado: (2022)

Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers
por: Ishida, Kazushige, et al.
Publicado: (2012)

S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis
por: He, Ming-ming, et al.
Publicado: (2013)

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients
por: LIANG, XU, et al.
Publicado: (2015)

Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient
por: Bukhari, Nedal, et al.
Publicado: (2019)

A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer
por: Lu, Zhihao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ej8cnrbvnlt5qrfp150c1la9gd